Jochle W, Moore J N, Brown J, Baker G J, Lowe J E, Fubini S, Reeves M J, Watkins J P, White N A
Wolfgang Jochle Associates Inc, Denville, New Jersey 07834, USA.
Equine Vet J Suppl. 1989 Jun(7):111-6. doi: 10.1111/j.2042-3306.1989.tb05668.x.
Detomidine hydrochloride, butorphanol tartrate, flunixin meglumine and xylazine hydrochloride were evaluated in a blind multi-centre clinical trial in 152 horses with abdominal pain. The drugs were administered as follows: detomidine 20 or 40 micrograms/kg bodyweight (bwt); butorphanol 0.1 mg/kg bwt; flunixin meglumine 1.0 mg/kg bwt; xylazine hydrochloride 0.5 mg/kg bwt. Each centre compared responses to the two doses of detomidine with those to one of the other analgesics. The drugs were administered intravenously (i.v.) after clinical assessment of the degree of sweating, kicking, pawing, head and body movement, attitude, lip curling, stretching to urinate, pulse rate, respiratory rate and rectal temperature. Similar assessments were repeated at 15 min intervals for at least 1 h. The investigators ranked the response to treatment from 'not satisfactory' to 'highly satisfactory'. Significant differences in sweating, kicking, pawing, head and body movement, attitude, pulse rate and respiratory rate were noted between the horses receiving butorphanol and either dose of detomidine. The investigators' subjective evaluation of the analgesic and sedative effects of either dose of detomidine were significantly better than for butorphanol. Analgesia was rated as highly satisfactory or satisfactory in 93.3 per cent and 6.7 per cent of the horses receiving 40 micrograms/kg bwt of detomidine, 73.3 per cent and 26.7 per cent of the horses receiving 20 micrograms/kg bwt of detomidine, and none of the horses receiving butorphanol. There were no differences in the incidence of side effects with the two compounds. Significant differences were noted in kicking, pawing, head and body movement and attitude between the horses receiving flunixin meglumine and either dose of detomidine. Flunixin meglumine provided significantly less analgesia than either dose of detomidine. Analgesia was rated as highly satisfactory or satisfactory in 73.7 per cent and 21.0 per cent of the horses receiving 40 micrograms/kg bwt of detomidine, 42.9 per cent and 21.4 per cent of the horses receiving 20 micrograms/kg bwt of detomidine, and 6.3 per cent and 37.5 per cent of the horses receiving xylazine. Sedation was considered to be at least satisfactory in 84.2 per cent of the horses receiving 40 micrograms/kg of detomidine, 71.5 per cent of the horses receiving 20 micrograms/kg of detomidine and 53.3 per cent of the horses receiving xylazine.
在一项针对152匹腹痛马的盲法多中心临床试验中,对盐酸地托咪定、酒石酸布托啡诺、氟尼辛葡甲胺和盐酸赛拉嗪进行了评估。给药方式如下:地托咪定20或40微克/千克体重(bwt);酒石酸布托啡诺0.1毫克/千克体重;氟尼辛葡甲胺1.0毫克/千克体重;盐酸赛拉嗪0.5毫克/千克体重。每个中心将两种剂量地托咪定的反应与其他一种镇痛药的反应进行比较。在对出汗、踢腿、刨地、头部和身体运动、姿势、卷唇、伸展排尿、脉搏率、呼吸率和直肠温度的程度进行临床评估后,通过静脉内(i.v.)给药。每隔15分钟重复进行类似评估,至少持续1小时。研究人员将治疗反应从“不满意”到“非常满意”进行排名。接受酒石酸布托啡诺和任一剂量地托咪定的马在出汗、踢腿、刨地、头部和身体运动、姿势、脉搏率和呼吸率方面存在显著差异。研究人员对地托咪定任一剂量的镇痛和镇静效果的主观评价明显优于酒石酸布托啡诺。接受40微克/千克体重地托咪定的马中,93.3%和6.7%的镇痛效果被评为非常满意或满意;接受20微克/千克体重地托咪定的马中,73.3%和26.7%的镇痛效果被评为非常满意或满意;而接受酒石酸布托啡诺的马中没有一匹的镇痛效果被评为非常满意或满意。两种化合物的副作用发生率没有差异。接受氟尼辛葡甲胺和任一剂量地托咪定的马在踢腿、刨地、头部和身体运动以及姿势方面存在显著差异。氟尼辛葡甲胺提供的镇痛效果明显低于任一剂量的地托咪定。接受40微克/千克体重地托咪定的马中,73.7%和21.0%的镇痛效果被评为非常满意或满意;接受20微克/千克体重地托咪定的马中,42.9%和21.4%的镇痛效果被评为非常满意或满意;接受盐酸赛拉嗪的马中,6.3%和37.5%的镇痛效果被评为非常满意或满意。接受40微克/千克地托咪定的马中,84.2%的镇静效果被认为至少满意;接受20微克/千克地托咪定的马中,71.5%的镇静效果被认为至少满意;接受盐酸赛拉嗪的马中,53.3%的镇静效果被认为至少满意。